Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.

Publication Type Academic Article
Authors Hu M, Liu D, Wortzel I, Collier P, Nelson T, Foox J, Zhong G, Tobias G, Asao T, Bojmar L, Kenific C, Wang G, Caielli S, Wan Z, Qureshy S, Reed M, Piszczatowski R, Ravisankar P, Brown J, Xiong S, Wang H, Lauritzen P, Aylon Y, Molina H, Jarnagin W, Oren M, Stanger B, Bui J, Bergers G, Noël A, Grandgenett P, Hollingsworth M, Tuveson D, Boudreau N, Bromberg J, Kelsen D, Jones D, Santambrogio L, Zeng M, Pascual V, Kim H, Mason C, Zhang H, Matei I, Lyden D
Journal Cancer Cell
Volume 44
Issue 5
Pagination 965-982.e12
Date Published 04/30/2026
ISSN 1878-3686
Keywords T-Lymphocytes, Lymphocyte Activation, Extracellular Vesicles, Antigen Presentation
Abstract Antigen processing and presentation (APP) is essential for adaptive immunosurveillance. We uncover a mechanism whereby activated T cell-derived extracellular vesicles (ATEVs) drive a positive feedback loop that enhances antigen presentation and immune responses in normal physiology and cancer. ATEV-induced immunogenicity relies on extracellular vesicular double-stranded DNA (EVDNA), which is notably abundant and primarily composed of genomic DNA enriched in immune-related genes, including those encoding APP machinery. Mechanistically, granzyme B (Gzmb) packaged by ATEVs disrupts the nuclear envelope of recipient cells, facilitating intranuclear transfer and subsequent transient expression of EVDNA encoding APP genes. DNase treatment removes most AT-EVDNA, abrogating APP upregulation and thus T cell activation and recruitment to tumors. Notably, ATEVs hold promise as an acellular immunotherapy, restoring APP and synergizing with checkpoint blockade in immunotherapy-refractory tumors. Collectively, our findings uncover a mechanism of transient, non-viral gene delivery by ATEVs that boosts APP and anti-tumor immunity while limiting autoimmunity.
DOI 10.1016/j.ccell.2026.03.023
PubMed ID 42066762
PubMed Central ID PMC13215210
Back to Top